Inventage Lab

Inventage Lab EBIT CAGR 5Y

The EBIT CAGR (5 Year) of Inventage Lab (389470.KQ) as of Nov 3, 2026 is 38.66 %. In the previous year, EBIT CAGR (5 Year) was 38.66 % — a change of 0.00% (lower).

EBIT CAGR 5Y

38.66 %

YoY

0.00%

Last updated:

EBIT CAGR (5 Year) of Inventage Lab is 2025 38.66 % . EBIT CAGR (5 Year) of Inventage Lab was 2024 38.66 % . It decreases by 0.00% lower compared to the previous year.

The Inventage Lab EBIT CAGR 5Y history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT CAGR 5Y
Date
EBIT CAGR 5Y
Jan 1, 2019
38.66 KRW
Jan 1, 2020
38.66 KRW
Jan 1, 2021
38.66 KRW
Jan 1, 2022
38.66 KRW
Jan 1, 2023
38.66 KRW
Jan 1, 2024
38.66 KRW
Jan 1, 2025
38.66 KRW
The Inventage Lab EBIT CAGR 5Y history
YEAREBIT CAGR 5YYoY
38.66 %0.00%
38.66 %0.00%
38.66 %0.00%
38.66 %0.00%
38.66 %0.00%
38.66 %0.00%
38.66 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Inventage Lab Stock analysis

What does Inventage Lab do? Inventage Lab, Inc. generates revenue through the research, manufacture, and sale of human medicines targeting male pattern baldness, dementia, and prostate cancer, as well as veterinary medicines including combination drugs and chemical castration agents. The company leverages its proprietary platforms for long-acting injections and genetic material drug delivery to develop and scale production of these products. Its human medicine segment focuses on therapeutic areas with significant market demand, while veterinary medicines serve agricultural and companion animal markets. The firm's business model centers on proprietary technology platforms applied to both human and veterinary pharmaceutical development. These platforms enable the company to create and mass-produce innovative drug delivery systems, which are critical for the efficacy of their medicine portfolios. Revenue streams are derived from direct sales of these medicines to healthcare providers and veterinary institutions within their target markets. Inventage Lab, Inc. operates with a dual focus on human and veterinary pharmaceuticals, utilizing its specialized platforms to address unmet medical needs in both sectors. The company's product range includes treatments for specific conditions like male pattern baldness and prostate cancer, alongside veterinary applications such as chemical castration agents, which are sold to relevant industry stakeholders in their respective markets. Inventage Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Inventage Lab stock

EBIT CAGR (5 Year) of Inventage Lab is 38.66 % in 2025.

On Eulerpool you can find the complete historical development of EBIT CAGR (5 Year) Inventage Lab since 2006 – with annual values, charts, and detailed analysis.

The 5-year EBIT CAGR shows the compound annual growth rate of EBIT over the past five years.

To evaluate EBIT CAGR (5 Year)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT CAGR (5 Year).

EBIT CAGR (5 Year)'s is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT CAGR (5 Year)'s Inventage Lab historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Inventage Lab

All Key Metrics — Inventage Lab